Treatment of osteoporosis in men

Bone

Volumn 53, Issue 1, 2013, Pages 134-144

  Kaufman, J M ^a   Reginster, J Y ^b   Boonen, S ^c   Brandi, M L ^d   Cooper, C ^e,f   Dere, W ^g   Devogelaer, J P ^h   Diez Perez, A ⁱ   Kanis, J A ^j   McCloskey, E ^j   Mitlak, B ^k   Orwoll, E ^l   Ringe, J D ^m   Weryha, G ⁿ   Rizzoli, R ^o  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g Université Catholique de Louvain ^*

^h UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k ELI LILLY AND COMPANY   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ UNIVERSITY HOSPITAL OF NANCY   (France)

^o GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Bone mineral density; Fracture risk; Gonadal hormone status; T score; Treatment

Indexed keywords

AGENTS AFFECTING METABOLISM; ALENDRONIC ACID; BETA CATENIN; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; ESTRADIOL; JTT 305; ODANACATIB; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN INHIBITOR; RISEDRONIC ACID; RONACALERET; SELECTIVE ANDROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TESTOSTERONE; UNCLASSIFIED DRUG; WNT PROTEIN; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; BONE TURNOVER; DRUG EFFICACY; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; INCIDENCE; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSTMENOPAUSE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SPINE FRACTURE; TREATMENT RESPONSE;

ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; MALE; MEN'S HEALTH; OSTEOPOROSIS;

EID: 84871826341     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.11.018     Document Type: Review

References (111)

1. Teng G.G., Curtis J.R., Saag K.G. Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?. Curr Osteoporos Rep 2009, 7:27-34.
2. Ebeling P.R. Clinical practice. Osteoporosis in men. N Engl J Med 2008, 358:1474-1482.
3. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:1726-1733.
4. Campion J.M., Maricic M.J. Osteoporosis in men. Am Fam Physician 2003, 67:1521-1526.
5. Kaufman J.M., Goemaere S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2008, 22:787-812.
6. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841-1850.
7. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010, 95:3-10.
8. Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., Delmas P., et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005, 20:1185-1194.
9. Kanis J.A., Bianchi G., Bilezikian J.P., Kaufman J.M., Khosla S., Orwoll E., et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 2011, 22:2789-2798.
10. Center J.R., Bliuc D., Nguyen T.V., Eisman J.A. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007, 297:387-394.
11. Curtis J.R., McClure L.A., Delzell E., Howard V.J., Orwoll E., Saag K.G., et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009, 24:956-962.
12. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475.
13. Ström O., Borgström F., Kanis J.A., Compston J., Cooper C., McCloskey E.V., et al. Osteoporosis; Burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011, 10.1007/s11657-11011-10060-11651.
14. Bilezikian J.P. Osteoporosis in men. J Clin Endocrinol Metab 1999, 84:3431-3434.
15. Harvey N., Dennison E., Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol 2010, 6:99-105.
16. Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A.K. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002, 17:1237-1244.
17. Sambrook P., Cooper C. Osteoporosis. Lancet 2006, 367:2010-2018.
18. Cooper C., Cole Z.A., Holroyd C.R., Earl S.C., Harvey N.C., Dennison E.M., et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011, 22:1277-1288.
19. Dhanwal D.K., Cooper C., Dennison E.M. Geographic variation in osteoporotic hip fracture incidence: the growing importance of Asian influences in coming decades. J Osteoporos 2010, 10.4061/2010/757102.
20. Dhanwal D.K., Dennison E.M., Harvey N.C., Cooper C. Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop 2011, 45:15-22.
21. Xia W.B., He S.L., Xu L., Liu A.M., Jiang Y., Li M., et al. Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 2011, 10.1002/jbmr.519.
22. Johnell O., Kanis J.A., Jonsson B., Oden A., Johansson H., De Laet C. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005, 16:222-228.
23. Orwig D.L., Chan J., Magaziner J. Hip fracture and its consequences: differences between men and women. Orthop Clin North Am 2006, 37:611-622.
24. Melton L.J., Kearns A.E., Atkinson E.J., Bolander M.E., Achenbach S.J., Huddleston J.M., et al. Secular trends in hip fracture incidence and recurrence. Osteoporos Int 2009, 20:687-694.
25. Hagino H., Sakamoto K., Harada A., Nakamura T., Mutoh Y., Mori S., et al. Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci 2010, 15:737-745.
26. Johansson H., Clark P., Carlos F., Oden A., McCloskey E.V., Kanis J.A. Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporos Int 2011, 22:2359-2364.
27. Kanis J.A., Melton L.J., Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
28. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J., Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008, 42:467-475.
29. Looker A.C., Wahner H.W., Dunn W.L., Calvo M.S., Harris T.B., Heyse S.P., et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998, 8:468-489.
30. Kanis J.A., Johnell O., Oden A., De Laet C., Mellstrom D. Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 2001, 69:218-221.
31. Selby P.L., Davies M., Adams J.E. Do men and women fracture bones at similar bone densities?. Osteoporos Int 2000, 11:153-157.
32. Orwoll E. Assessing bone density in men. J Bone Miner Res 2000, 15:1867-1870.
33. Nguyen T., Sambrook P., Kelly P., Jones G., Lord S., Freund J., et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993, 307:1111-1115.
34. Melton L.J., Atkinson E.J., O'Connor M.K., O'Fallon W.M., Riggs B.L. Bone density and fracture risk in men. J Bone Miner Res 1998, 13:1915-1923.
35. Lunt M., Felsenberg D., Reeve J., Benevolenskaya L., Cannata J., Dequeker J., et al. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 1997, 12:1883-1894.
36. Cummings S.R., Cawthon P.M., Ensrud K.E., Cauley J.A., Fink H.A., Orwoll E.S. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006, 21:1550-1556.
37. De Laet C.E., van Hout B.A., Burger H., Hofman A., Pols H.A. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997, 315(7102):221-225.
38. De Laet C.E., Van Hout B.A., Burger H., Weel A.E., Hofman A., Pols H.A. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998, 13(10):1587-1593.
39. Wasnich R.D., Davis J.W., Ross P.D. Spine fracture risk is predicted by non-spine fractures. Osteoporos Int 1994, 4:1-5.
40. Lewis C.E., Ewing S.K., Taylor B.C., Shikany J.M., Fink H.A., Ensrud K.E., et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007, 22:211-219.
41. Fink H., Litwack-Harrison S., Ensrud K., Orwoll E., Bauer D. What is the value of laboratory testing to identify possible secondary contributors to osteoporosis in older men?. Proceedings of the American Society for Bone and Mineral Research (ASBMR), San Diego, CA; USA 2011, S339. [Abstract SU0348].
42. Luukinen H., Kakonen S.M., Pettersson K., Koski K., Laippala P., Lovgren T., et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 2000, 15:2473-2478.
43. Meier C., Nguyen T.V., Center J.R., Seibel M.J., Eisman J.A. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 2005, 20:579-587.
44. Bauer D.C., Garnero P., Harrison S.L., Cauley J.A., Eastell R., Ensrud K.E., et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 2009, 24:2032-2038.
45. Szulc P., Montella A., Delmas P.D. High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis 2008, 67:1249-1255.
46. Vasikaran S., Eastell R., Bruyere O., Foldes A.J., Garnero P., Griesmacher A., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
47. Khosla S., Riggs B.L., Atkinson E.J., Oberg A.L., McDaniel L.J., Holets M., et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006, 21:124-131.
48. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
49. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395-1408.
50. Kanis J.A. on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical Report 2008, World Health Organization Collaborating Centre for Metabolic Bone Diseases. University of Sheffield, UK.
51. Royal College of Physicians Clinical Guidelines for the Prevention and Treatment of Osteoporosis 1999, RCP, London, UK.
52. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
53. Committee for Medicinal Products for Human Use (CHMP) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis 2006, London, Doc. Ref. CPMP/EWP/552/95 Rev. 2;.
54. Colman E.G. The Food and Drug Administration's Osteoporosis Guidance Document: past, present, and future. J Bone Miner Res 2003, 18:1125-1128.
55. Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604-610.
56. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
57. Pols H.A., Felsenberg D., Hanley D.A., Stepan J., Munoz-Torres M., Wilkin T.J., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999, 9:461-468.
58. Boonen S., Vanderschueren D., Geusens P., Bouillon R. Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 1997, 20:134-143.
59. Boonen S., Orwoll E.S., Wenderoth D., Stoner K.J., Eusebio R., Delmas P.D. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009, 24:719-725.
60. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
61. Ringe J.D., Farahmand P., Faber H., Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009, 29:311-315.
62. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
63. Boonen S., Orwoll E., Magaziner J., Colon-Emeric C.S., Adachi J.D., Bucci-Rechtweg C., et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 2011, 59:2084-2090.
64. Orwoll E.S., Miller P.D., Adachi J.D., Brown J., Adler R.A., Kendler D., et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25:2239-2250.
65. Boonen s., Reginster J.-Y., Kaufman J.-M., Lippuner K., Zanchetta J., Langdahl B., et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012, 367:1714-1723.
66. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
67. Reeve J., Meunier P.J., Parsons J.A., Bernat M., Bijvoet O.L., Courpron P., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980, 280:1340-1344.
68. Slovik D.M., Rosenthal D.I., Doppelt S.H., Potts J.T., Daly M.A., Campbell J.A., et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986, 1:377-381.
69. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
70. Tashjian A.H., Chabner B.A. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002, 17:1151-1161.
71. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
72. Kaufman J.M., Orwoll E., Goemaere S., San Martin J., Hossain A., Dalsky G.P., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
73. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Mautalen C., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
74. Leder B.Z., Neer R.M., Wyland J.J., Lee H.W., Burnett-Bowie S.M., Finkelstein J.S. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 2009, 94:2915-2921.
75. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
76. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
77. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004, 19:1259-1269.
78. Wong M., Wan X., Ruff V., Krohn K., Taylor K. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 2011, 10.1007/s00198-011-1725-8.
79. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
80. Finkelstein J.S., Leder B.Z., Burnett S.M., Wyland J.J., Lee H., de la Paz A.V., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006, 91:2882-2887.
81. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
82. Cosman F., Eriksen E.F., Recknor C., Miller P.D., Guanabens N., Kasperk C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
83. Smith M.R. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007, 14:247-254.
84. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
85. Amin S., Zhang Y., Sawin C.T., Evans S.R., Hannan M.T., Kiel D.P., et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000, 133:951-963.
86. Van Pottelbergh I., Goemaere S., Kaufman J.M. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003, 88:3075-3081.
87. Amin S., Zhang Y., Felson D.T., Sawin C.T., Hannan M.T., Wilson P.W., et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006, 119:426-433.
88. Mellstrom D., Vandenput L., Mallmin H., Holmberg A.H., Lorentzon M., Oden A., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008, 23:1552-1560.
89. Doran P.M., Riggs B.L., Atkinson E.J., Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001, 16:2118-2125.
90. Uebelhart B., Herrmann F., Pavo I., Draper M.W., Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 2004, 19:1518-1524.
91. Smith M.R., Fallon M.A., Lee H., Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841-3846.
92. Rachner T.D., Khosla S., Hofbauer L.C. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287.
93. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
94. Orwoll E.S., Stubbe Teglbjærg C., Chapurlat R., Czerwinski E., Kendler D.L., Reginster J.-Y., et al. A phase 3 study of the efficacy and safety of denosumab in men with low bone mineral density: design of the ADAMO trial. USA J Bone Miner Res 2011, 26:S511. [Abstract MO0442].
95. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
96. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
97. Kaufman J-M, Ringe J-D, Felsenberg D, Audran M, Bianchi G, Boonen S, et al. Efficacy and safety of strontium ranelate in the treatment of male osteoporosis. Proceedings of the European Congress on Osteoporosis & Osteoarthritis (ECCEO11-IOF), Valencia, Spain Osteoporos Int 201; Abstract OC41: 2011.
98. Ringe J.D., Dorst A., Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 2010, 60:267-272.
99. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25:937-947.
100. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26:242-251.
101. Moester M.J., Papapoulos S.E., Lowik C.W., van Bezooijen R.L. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010, 87:99-107.
102. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
103. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2010, 26:19-26.
104. Fitzpatrick L., Dabrowski C., Cicconetti G., Papapoulos S., Bone H., Bilezikian J. Ronacaleret, a calcium-sensing receptor antagonist: results of a 1 year double-blind, placebo-controlled, dose-ranging phase II study. USA J Bone Miner Res 2009, 24 (S1):S40. [Abstract 1130].
105. Fukumoto S., Nakamura T., Nishizawa Y., Hayashi M., Matsumoto T. Randomized, single-blinded placebo-controlled study of a novel calcilytic, JTT-305, in patients with postmenopausal osteoporosis. USA J Bone Miner Res 2009, 24 (S1):S40. [Abstract 1131].
106. Baron R., Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
107. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
108. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009, 119:837-851.
109. Gao W., Reiser P.J., Coss C.C., Phelps M.A., Kearbey J.D., Miller D.D., et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 146:4887-4897.
110. Yarrow J.F., Conover C.F., McCoy S.C., Lipinska J.A., Santillana C.A., Hance J.M., et al. 17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab 2011, 300:E650-E660.
111. World Health Organization Guidelines for preclinical evaluation and clinical trials in osteoporosis 1998, WHO, Geneva, Switzerland.